Supraspinal Processing of Sensory Aspects of Pain
Children's Hospital Medical Center, Cincinnati · with University of Barcelona · NCT05814497
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 10–17 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 255
- US sites recruiting
- 1
- Study start
- May 1, 2023
- Record last updated
- June 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this basic science study is to learn about the brain mechanisms of chronic pain across different chronic pain syndromes in pediatric patients. The main questions it aims to answer are:
- Are there shared and distinct brain systems engaged by different forms of pediatric chronic pain?
- What are predictors of recovery from chronic pain?
- What brain systems are associated with the spread of pain?
For this study participants will undergo
- Functional Magnetic Resonance Imaging (fMRI)
- Quantitative Sensory Testing
- Psychological Assessments
Being studied: Multisensory Task; Graphesthesia; Divided attention
Conditions: Migraine in Children; Complex Regional Pain Syndromes; Musculoskeletal Pain; Functional Abdominal Pain Syndrome; Fibromyalgia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patients will need a diagnosis of a chronic pain derived congruent with ICD-11 criteria related to headache (migraine, daily headache), abdominal (FAPD), localized MSK (single limb/joint, low back or chest pain), diffuse MSK (widespread MSK pain), or CRPS
- If on medications, they need to be on stable doses of prescribed pain and/or psychiatric medications for 4 weeks before the baseline study visit.
- Male or female, age 10 -17 (inclusive)
- English speaking, able to complete interviews and questionnaires in English
Exclusion Criteria
- Weight/size incompatible with MRI scanner
- Orthodontic braces, metallic or electronic implants, or other metal objects in the body which obscure or interfere with the MRI, or pose a risk from heating, movement, or malfunction in the MRI environment
- Claustrophobia
- Youth who are pregnant
- Any comorbid rheumatic disease, diagnosis of epilepsy, other neurological diseases, or medical condition (e.g. diabetes, cancer, IBD)
- Present psychiatric disease as defined by DSM IV (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, ADHD, or mental retardation) that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study
- Skin conditions or past skin damage on the arms or legs in or near sites of sensory testing
- Outside the age range (9 years old or younger; 18 years or older) at the time of consent
- History of > 1 month opioid treatment.
Recruiting US locations
Cincinnati Children's Hospital
Cincinnati, OH 45229
Site contact: Catherine Jackson, MSc · 513-636-0669 · Catherine.Jackson@cchmc.org
Study contacts (from the official record)
- Catherine Jackson, MSc · 5136360669 · Catherine.Jackson@cchmc.org
- Hannah Schildmeyer, BS · Hannah.Schildmeyer@cchmc.org
Similar studies in Ohio
All neurology studies in Ohio →- RecruitingHealthy volunteers
A Study to Evaluate the SENSE Device's Ability to Detect TBI
Sense Diagnostics, LLC
- Location
- Cincinnati, OH + 5 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Columbus, OH + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 3
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd.
- Location
- Beachwood, OH + 16 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Cincinnati, OH + 35 other US sites
- Eligibility basics
- Ages 18–65